Guarana for cancer-related fatigue

Evidence label: Mixed / uncertain · Clinical goal: reduce fatigue during chemotherapy or chemoradiotherapy

Evidence at a glance

Population: people receiving breast-cancer chemotherapy, head-and-neck chemoradiotherapy or other systemic treatment.
Intervention: dry Paullinia cupana (guarana) extract, commonly 50 mg twice daily in the direct trials.
Result: one small breast-cancer trial was positive, while other randomized trials were negative or stopped early; pooled estimates are heterogeneous.

What was studied

A 75-person breast-cancer study randomized participants with worsening fatigue after cycle one to guarana 50 mg twice daily (32) or placebo (43) for 21 days.

A separate double-blind phase II study randomized 60 people receiving head-and-neck chemoradiotherapy to the same nominal dose or placebo. Other studies tested post-radiation fatigue and a purified extract across solid tumors.

What the evidence shows

The breast-cancer trial reported improved fatigue, but the 60-person head-and-neck trial found no benefit and concluded that guarana was not useful in that setting. A post-radiation breast-cancer pilot was also negative, and a broader solid-tumor study stopped early.

Meta-analyses differ: a 2024 analysis reported a pooled benefit with high heterogeneity, while a 2026 phytotherapy meta-analysis did not find a statistically significant guarana subgroup. This pattern is not a dependable clinical effect.

Limits and uncertainty

Trials were small, used different extracts, populations and fatigue scales, and often had short follow-up. High heterogeneity means a pooled average may hide incompatible studies.

Some sources were accessible only as abstracts; unreported adherence, attrition and funding details are marked as not independently verified.

Safety and practical context

Guarana naturally contains caffeine and other stimulants. Possible concerns include insomnia, anxiety, palpitations, blood-pressure elevation and interaction with other stimulants or medicines.

Fatigue during treatment still requires assessment for anemia, infection, endocrine problems, dehydration, sleep disturbance, mood symptoms and cancer activity.

Questions for the care team

How much caffeine is in the exact product and what other stimulants am I using?
Has a reversible medical cause of fatigue been checked?
What improvement and stop rule would make a short monitored trial worthwhile?

Sources

Literature searched: October 15, 2026 · Record appraised: October 15, 2026

Educational evidence summary, not personal medical advice. Research regimens describe what was studied; they are not personal prescribing instructions and should not replace cancer treatment or individualized supportive care.